What is Poolbeg Pharma PLC?
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom.
POLBF · Verdict
Limited reward · elevated risk
POLBF's standout is balance sheet; cash flow and volatility weigh on the picture.
Based on 88% data coverage
POLBF · Verdict
Current ratio 8.79
Weak vs peers
Weak vs peers
-47% return on equity
Earnings +35.3% CAGR
Model-based scoring. For information only — not financial advice.
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 46.61M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.